Bioxytran (Bioxytran) Retained Earnings : $-16.30 Mil (As of Mar. 2024)

View and export this data going back to 2009. Start your Free Trial

What is Bioxytran Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Bioxytran's retained earnings for the quarter that ended in Mar. 2024 was $-16.30 Mil.

Bioxytran's quarterly retained earnings declined from Sep. 2023 ($-14.45 Mil) to Dec. 2023 ($-15.50 Mil) and declined from Dec. 2023 ($-15.50 Mil) to Mar. 2024 ($-16.30 Mil).

Bioxytran's annual retained earnings declined from Dec. 2021 ($-8.75 Mil) to Dec. 2022 ($-11.22 Mil) and declined from Dec. 2022 ($-11.22 Mil) to Dec. 2023 ($-15.50 Mil).

Bioxytran Retained Earnings Historical Data

The historical data trend for Bioxytran's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bioxytran Retained Earnings Chart

Bioxytran Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Retained Earnings

Get a 7-Day Free Trial

-2.24

-4.72

-8.75

-11.22

-15.50

Bioxytran Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Retained Earnings	Get a 7-Day Free Trial															-12.00	-13.41	-14.45	-15.50	-16.30

Bioxytran Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Bioxytran (OTCPK:BIXT) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.

Bioxytran (Bioxytran) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bioxytran Inc (OTCPK:BIXT) » Definitions » Retained Earnings

Comparable Companies

Traded in Other Exchanges

N/A

Address

75 2nd Avenue, Suite 605, Needham, MA, USA, 02494

Website

https://www.bioxytraninc.com

Bioxytran Inc is a biopharmaceutical company. The company is engaged in developing anti-necrosis drugs that treat a variety of medical conditions resulting from Ischemia. It is also focusing on the development and commercialization of treatments to prevent catastrophic brain damage resulting from hypoxic conditions following brain stroke. Its product candidate, BXT-25, is an anti-necrosis drug that carries oxygen to tissues when the flow of blood is blocked. Its other drug candidate BXT-252 is a resuscitative agent in a variety of wound healing applications.

Executives

Dale H Conaway	director	189 WELLS AVE, NEWTON MA 02459
Alan M Hoberman	director	6134 MECHANICSVILLE ROAD, PO BOX 56, MECHANICSVILLE PA 18934
Anders Utter	director	BIOXYTRAN, INC, 233 NEEDHAM ST., SUITE 300, NEWTON MA 02464
David Platt	director, 10 percent owner, officer: CEO	12 APPLETON CIRCLE, NEWTON MA 02459
Hana Chen-walden	director	7 RUE ARISTIDE MAILLOL, PARIS I0 75015
Michael Sheikh	officer: Chief Communication Officer	1905 S AUDUBON CT, SPOKANE WA 99224
Binder Offer	other: No longer 10% owner	PASQUALE VIA SETTEMBRIMI 14A, SAN MARIANO 06073, CORCIANO PG ITALY L6 00000
Ola Soderquist	10 percent owner, officer: CFO	47 HAMMOND STREET, UNIT 2, WALTHAM MA 02451
Lawrence W. Bonafide	director	78365 HWY 111, SUITE 287, LA QUINTA CA 92253
Nathan Marks	director	78365 HWY 111, SUITE 287, LA QUINTA CA 92253
Dave Quincy Farber	director, officer: President	78365 HWY 111, SUITE 287, LA QUINTA CA 92253
David Lee	director	78365 HWY 111, SUITE 287, LA QUINTA CA 92253
Donita R. Kendig	director, officer: Secretary/Treasurer	78365 HWY 11, SUITE 287, LA QUINTA CA 92253
Afcc, Llc	10 percent owner	1621 CENTRAL AVENUE, CHEYENNE WY 82001
Paul W Hai	10 percent owner	20443 TIMBERLINE, BEND OR 97701